Immune Design is a clinical stage immunotherapy company employing next-generation in vivo approaches to enable the body’s immune system to fight disease. The company’s technologies are engineered to activate the immune system’s natural ability to create tumor-specific cytotoxic T cells to fight cancer and other chronic diseases. Immune Design’s clinical programs are the product of its two synergistic discovery platforms: ZVexTM and GLAASTM.
Apr 20, 2017
Mar 7, 2017
Immune Design Reports Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update
Mar 8, 2017 at 8:40 AM ET